ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer

Lung Cancer

Volumn 59, Issue 3, 2008, Pages 377-384

  Fujii, Tetsuya ^a   Toyooka, Shinichi ^a   Ichimura, Kouichi ^a   Fujiwara, Yoshiro ^a   Hotta, Katsuyuki ^a   Soh, Junichi ^a   Suehisa, Hiroshi ^a   Kobayashi, Naruyuki ^a   Aoe, Motoi ^a   Yoshino, Tadashi ^a   Kiura, Katsuyuki ^a   Date, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

BRCA1; Cisplatin; ERCC1; Neoadjuvant therapy; NSCLC; Radiation

Indexed keywords

BRCA1 PROTEIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; IRINOTECAN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE FRACTIONATION; SURVIVAL; THORACOTOMY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRCA1 PROTEIN; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; CISPLATIN; COMBINED MODALITY THERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 40249094603     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.08.025     Document Type: Article

References (31)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA Cancer J Clin 56 (2006) 106-130
2. Stinchcombe T.E., Fried D., Morris D.E., and Socinski M.A. Combined modality therapy for stage III non-small cell lung cancer. Oncologist 11 (2006) 809-823
3. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
4. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13 (2004) 2443-2449
5. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K., Danenberg P., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
6. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
7. Date H., Kiura K., Ueoka H., Tabata M., Aoe M., Andou A., et al. Preoperative induction chemotherapy with cisplatin and irinotecan for pathological N(2) non-small cell lung cancer. Br J Cancer 86 (2002) 530-533
8. Katayama H., Ueoka H., Kiura K., Tabata M., Kozuki T., Tanimoto M., et al. Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 90 (2004) 979-984
9. Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5 (1982) 649-655
10. The Japan Lung Cancer Society. General rule for clinical and pathological record of lung cancer. 6th ed. (2003), Kanehara, Tokyo
11. Adelstein D.J., Rice T.W., Rybicki L.A., Larto M.A., Ciezki J., Saxton J., et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 18 (2000) 2032-2039
12. Lawley P.D., and Phillips D.H. DNA adducts from chemotherapeutic agents. Mutat Res 355 (1996) 13-40
13. De Silva I.U., McHugh P.J., Clingen P.H., and Hartley J.A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 20 (2000) 7980-7990
14. Hoeijmakers J.H. Genome maintenance mechanisms for preventing cancer. Nature 411 (2001) 366-374
15. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16 (1998) 309-316
16. Dabholkar M., Bostick-Bruton F., Weber C., Bohr V.A., Egwuagu C., and Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84 (1992) 1512-1517
17. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., Provencio M., et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25 (2007) 2747-2754
18. Wang H., Zeng Z.C., Bui T.A., DiBiase S.J., Qin W., Xia F., et al. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2. Cancer Res 61 (2001) 270-277
19. Husain A., He G., Venkatraman E.S., and Spriggs D.R. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 58 (1998) 1120-1123
20. Simon G.R., Sharma S., Cantor A., Smith P., and Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 127 (2005) 978-983
21. Zheng Z., Chen T., Li X., Haura E., Sharma A., and Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
22. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., and Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50 (2005) 211-219
23. Vallbohmer D., Iqbal S., Yang D.Y., Rhodes K.E., Zhang W., Gordon M., et al. Molecular determinants of irinotecan efficacy. Int J Cancer 119 (2006) 2435-2442
24. Murray D., and Rosenberg E. The importance of the ERCC1/ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathway. Mutat Res 364 (1996) 217-226
25. Brodie S.G., Xu X., Qiao W., Li W.M., Cao L., and Deng C.X. Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice. Oncogene 20 (2001) 7514-7523
26. Caffo O. Radiosensitization with chemotherapeutic agents. Lung Cancer 34 Suppl. 4 (2001) S81-S90
27. Rosell R., Cobo M., Isla D., Camps C., and Massuti B. Pharmacogenomics and gemcitabine. Ann Oncol 17 Suppl. 5 (2006) v13-v16
28. Britten R.A., Liu D., Tessier A., Hutchison M.J., and Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 89 (2000) 453-457
29. Niedernhofer L.J., Bhagwat N., and Wood R.D. ERCC1 and non-small-cell lung cancer. N Engl J Med 356 (2007) 2538-2540 author reply 2540-31
30. Murray D., Mirzayans R., Scott A.L., and Allalunis-Turner M.J. Influence of oxygen on the radiosensitivity of human glioma cell lines. Am J Clin Oncol 26 (2003) e169-e177
31. Kwon H.C., Roh M.S., Oh S.Y., Kim S.H., Kim M.C., Kim J.S., et al. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18 (2007) 504-509